FDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents ItselfSeeking Alpha • 01/20/20
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The LancetGlobeNewsWire • 12/06/19
Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/19
This Biotech Flew To A 7-Month High On A Double Serving Of Good NewsInvestors Business Daily • 11/25/19
Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/05/19
Intercept Announces New NASH and PBC Data to be Presented at The Liver Meeting® 2019GlobeNewsWire • 10/28/19
Analysts Estimate Intercept Pharmaceuticals (ICPT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/23/19
Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASHGlobeNewsWire • 09/27/19